Efficacy and Safety of Long-Term Azathioprine Therapy for Severe Alopecia Areata: A 10-Year Cohort Study

April 2025 in “ Journal of Cosmetic Dermatology ”

Susan Farshi, Parvin Mansouri

azathioprine alopecia areata hair regrowth systemic monotherapy

Studysummary In this study, researchers found that azathioprine significantly improved hair regrowth in patients with moderate to severe alopecia areata over 10 years, with hair loss decreasing from 74.2% to 5.2% and demonstrating long-term safety and efficacy.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

research Alopecia Areata: Current Treatments and New Directions

57 citations , August 2023 in “American Journal of Clinical Dermatology”

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

66 citations , June 2021 in “Journal of The American Academy of Dermatology”

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

research Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate-to-Severe Alopecia Areata

10 citations , July 2019 in “Indian Journal of Dermatology”

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents

28 citations , December 2017 in “Journal of Investigative Dermatology Symposium Proceedings”

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

research Diagnosis and Management of Alopecia in Children

51 citations , January 2014 in “Pediatric Clinics of North America”

This article examines various types of childhood alopecia and highlights the importance of identifying chronic conditions or those linked to underlying medical issues, but reports no new results.

research Current Treatment of Alopecia Areata

71 citations , December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.

research Cure of Alopecia Areata After Eradication of Helicobacter Pylori: A New Association?

26 citations , July 2011 in “PubMed”

The authors report a case where alopecia areata went into remission after H. pylori eradication, suggesting a potential link that could expand treatment options if further studies confirm it.

research Alopecia Areata: Evidence-Based Treatments

71 citations , March 2009 in “Seminars in cutaneous medicine and surgery”

This review discusses evidence for alopecia areata treatments, highlighting their ability to stimulate hair growth but noting limited data on long-term efficacy and impact on quality of life.

research Interventions for Alopecia Areata

2 citations , February 2009 in “Journal of Evidence-Based Medicine”

This review of randomized controlled trials for alopecia areata treatments found that none were significantly better than placebo in promoting long-term hair growth, with most trials being small and poorly reported.

research Lymphocytes, Neuropeptides, And Genes Involved In Alopecia Areata

286 citations , August 2007 in “Journal of Clinical Investigation”

This review examines the interplay of genetics and neuroimmunology in alopecia areata, highlighting its potential to inform broader autoimmunity research, but reports no new findings.

research Alopecia Areata: Overview and Treatment Options

151 citations , February 2007 in “International Journal of Dermatology”

This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.